Eventide Asset Management LLC Acquires 785,557 Shares of Kestra Medical Technologies, Ltd. $KMTS

Eventide Asset Management LLC raised its holdings in shares of Kestra Medical Technologies, Ltd. (NASDAQ:KMTS) by 285.7% in the second quarter, Holdings Channel reports. The institutional investor owned 1,060,557 shares of the company’s stock after buying an additional 785,557 shares during the quarter. Eventide Asset Management LLC’s holdings in Kestra Medical Technologies were worth $17,584,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds have also bought and sold shares of the company. Quarry LP acquired a new position in Kestra Medical Technologies during the 1st quarter valued at $33,000. Police & Firemen s Retirement System of New Jersey bought a new position in shares of Kestra Medical Technologies during the 2nd quarter worth about $54,000. New York State Common Retirement Fund acquired a new position in shares of Kestra Medical Technologies during the second quarter valued at about $93,000. Virtu Financial LLC bought a new stake in shares of Kestra Medical Technologies in the first quarter valued at about $210,000. Finally, Walleye Capital LLC acquired a new stake in Kestra Medical Technologies during the second quarter worth about $166,000.

Analyst Ratings Changes

Several equities analysts have commented on the company. Wall Street Zen cut Kestra Medical Technologies from a “hold” rating to a “sell” rating in a report on Sunday, September 28th. BTIG Research began coverage on Kestra Medical Technologies in a research note on Tuesday, November 18th. They issued a “buy” rating and a $32.00 target price for the company. Wells Fargo & Company lifted their price target on shares of Kestra Medical Technologies from $27.00 to $28.00 and gave the stock an “overweight” rating in a research note on Friday. Weiss Ratings reissued a “sell (d)” rating on shares of Kestra Medical Technologies in a report on Wednesday, October 8th. Finally, Piper Sandler raised their price objective on shares of Kestra Medical Technologies from $27.00 to $30.00 and gave the stock an “overweight” rating in a report on Friday. Six equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, Kestra Medical Technologies has an average rating of “Moderate Buy” and a consensus target price of $29.14.

Kestra Medical Technologies Stock Performance

Kestra Medical Technologies stock opened at $26.17 on Friday. The firm has a market capitalization of $1.35 billion and a P/E ratio of -10.26. The stock has a fifty day moving average price of $25.54 and a two-hundred day moving average price of $20.81. Kestra Medical Technologies, Ltd. has a 52-week low of $13.25 and a 52-week high of $30.00. The company has a debt-to-equity ratio of 0.23, a current ratio of 6.84 and a quick ratio of 6.84.

Kestra Medical Technologies (NASDAQ:KMTS) last posted its earnings results on Thursday, September 11th. The company reported ($0.50) earnings per share for the quarter, topping the consensus estimate of ($0.66) by $0.16. The firm had revenue of $19.37 million during the quarter, compared to the consensus estimate of $17.68 million.

About Kestra Medical Technologies

We are a commercial-stage, wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. We have developed and are commercializing our Cardiac Recovery System platform, a comprehensive and advanced system that integrates monitoring, therapeutic treatment, digital health, and patient support services into a single, unified solution.